|
 |
TrelstarThis page contains recent news articles, when available, and an overview of Trelstar but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR®, for the treatment of advanced prostate cancer ... CNNMoney.com (press release) Paladin Reports Record Third Quarter 2009 Financial Results - Nov 11, 2009 Pennsaid(R), Metadol(R), Trelstar(R), and Testim(R) which increased by 10% in the third quarter of 2009 compared to the corresponding period a year ago. ... Benzinga Watson Pharmaceuticals Q3 2009 Earnings Call Transcript - Nov 4, 2009 During the quarter we responded to FDA's complete response letter regarding our six month formulation of TRELSTAR. That submission is under active review ... Seeking Alpha (blog) Paladin déclare des résultats financiers record pour le troisième trimestre 2009 - Nov 11, 2009 Trelstar(MD) et Testim(MD) dont les ventes ont augmenté de 10 % au troisième trimestre 2009 comparativement à la même période de l'année précédente. ... Maketwire (Communiqué de presse) Watson Phamaceuticals gets FDA OK for new syringe - Apr 30, 2008 The syringe, known as Mixject, will be used with Watson's Trelstar LA and Trelstar Depot which contain a synthetic hormone to treat advanced prostate cancer ... Boston Globe … ' TRELSTAR(R) DEPOT and TRELSTAR(R) LA (Triptorelin Pamoate for … - Apr 4, 2005 CORONA, Calif., April 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, has made available nationwide ... RedOrbit … ' TRELSTAR(R) DEPOT and TRELSTAR(R) LA (Triptorelin Pamoate for … - Apr 4, 2005 Watson Pharmaceuticals' TRELSTAR(R) DEPOT and TRELSTAR(R) LA (Triptorelin Pamoate for Injectable Suspension) Now Available Nationwide. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … submits NDA for a 6-month formulation of Trelstar for the treatment... - Nov 14, 2008 Watson submits NDA for a 6-month formulation of Trelstar for the treatment of advanced prostate cancer. M2 EUROPHARMA-(C)1999-2008 M2 COMMUNICATIONS LTD ... $9.94 - M2 Europharma - Alacra Store Paladin Reports Record Second Quarter Results and Provides Upward … - Aug 3, 2006 In the third quarter, we will be launching Trelstar ® (LHRH) and Vantas ... We are confident that Trelstar ® and Trelstar ® LA have the potential to make a ... ccnmatthews.com … Enter Into Marketing and Supply Agreement for Trelstar'R' in... - May 2, 2005 Trelstar(R) 3.75 mg and Trelstar(R) LA 11.25 mg are approved for sale in Canada. "Trelstar(R) represents our third product deal with Watson and follows on ... $4.95 - Business Wire - ECNext … Release: Debiopharm Announces US NDA Filing of Trelstar(R) 6-Month... - Nov 13, 2008 Debiopharm Announces US NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for... - Nov 13, 2008 Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer. from PR Newswire ... Pay-Per-View - PR Newswire - HighBeam Research Paladin Reports 2007 Record Third Quarter Financial Results - Nov 1, 2007 These increases are due primarily to strong performance from the Company's key promoted products, including Twinject®, Oxytrol®, Testim®, Plan B®, Trelstar® ... Web Services Journal - Web Services Journal Press Release: FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use … - Apr 30, 2008 Article: Debiopharm Announces U.S. NDA Filing of Trelstar 6-Month . ... Trelstar(R) 3.75 mg ... treatment of advanced prostate cancer and Trelstar(R) 3.75 ... Pay-Per-View - PR Newswire - HighBeam Research Trelstar cleared. - May 2, 2005 Watson Pharmaceuticals Inc. says Trelstar Depot and Trelstar LA are now available nationwide. The products are palliative treatments for advanced prostate ... $9.94 - Chain Drug Review - Alacra Store Article: Trelstar cleared.(RXs)(Brief Article) - Chain Drug Review | ... - May 2, 2005 Trelstar cleared.(RXs)(Brief Article) ... find Chain Drug Review articles. Pay-Per-View - Chain Drug Review - HighBeam Research Press Release: Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month … - Feb 12, 2008 Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Watson's Trelstar is launched in USA.(Pharmaceutical industry)(Brief ... - Apr 11, 2005 Watson Pharmaceuticals of the USA has launched two anti-testosterone treatments Trelstar depot and Trelstar LA (triptorelin pamoate for injectable ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Watson Announces Silodosin NDA Accepted for Filing by FDA for the … - Feb 12, 2008 The Watson portfolio in the US includes Oxytrol(R); Trelstar(R) LA; Trelstar(R) Depot; Androderm(R); AndroGel(R), under a co-promotion agreement with Solvay ... Free with registration - PR Newswire - AccessMyLibrary.com Watson Announces Positive Data for Its New Investigational Products... - May 21, 2008 MIXJECT(R) combines the proven efficacy of TRELSTAR(R) with new features that make ... TRELSTAR(R) does not require refrigeration and should be stored at ... RedOrbit Advanced Stage Palliative Prostate Cancer Treatment to Be Offered... - Apr 11, 2005 TRELSTAR(R) DEPOT and TRELSTAR(R) LA (triptorelin pamoate for injectable ... TRELSTAR(R) is contraindicated for use in women who are or may become pregnant. ... $4.95 - PR Newswire - ECNext Finance; Paladin reports record second-quarter results and provides … - Sep 5, 2006 Trelstar and Trelstar LA have been approved for listing in Quebec by The Conseil du ... In the third quarter, we will be launching Trelstar and Vantas ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Watson Pharmaceuticals Reports Third Quarter 2007 Results. - Nov 6, 2007 Finally, Debiopharm, Watson's partner on Trelstar(R), completed the Phase 3 program for its 6-month formulation of Trelstar(R), an investigational product ... Free with registration - PR Newswire - AccessMyLibrary.com Event Brief of Q2 2006 Watson Pharmaceuticals, Inc. Earnings … - Aug 8, 2006 First of all, there was mention of Trelstar pricing pressure. ... There's a couple of factors that affect the Trelstar pricing from externally. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Paladin annonce ses résultats du deuxième trimestre et révise à la … - Aug 3, 2006 Nous sommes convaincus que Trelstar(MD) et Trelstar(MD) LA pourront faire une ... Trelstar(MD) renforce le positionnement de Paladin dans le domaine de ... ccnmatthews.com Press Release: Advanced Stage Palliative Prostate Cancer Treatment to... - Apr 11, 2005 TRELSTAR(R), together with the Clip'n'Ject(R) reconstitution system, was made available in ... ABOUT TRELSTAR(R). Read all of this article with a FREE trial ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q4 2005 Watson Pharmaceuticals, Inc. Earnings … - Feb 16, 2006 In specialty product, WPI launched TRELSTAR, which achieved ... Last year, Trelstar exceeded original forecast by many million dollars. 2. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Paladin enregistre des résultats record pour le quatrième trimestre... - Feb 28, 2008 Les efforts de promotion que nous avons consacrés à Trelstar(MD), Twinject(MD), Plan B(MD), Pennsaid(MD) et Testim(MD) ont contribué à notre forte ... marketwire.com Paladin Reports Record 2005 Fourth Quarter and Year End Results: … - Feb 22, 2006 Trelstar ® compliments our established urology franchise with Oxytrol ® and Vantas ® ... Paladin expects to launch Trelstar ® in the second half of 2006. ... ccnmatthews.com Paladin Reports 2007 Record Second Quarter Financial Results - Aug 2, 2007 Our promotional efforts behind the launch of Testim ® , Trelstar ® , Twinject ® , Metadol ® and the continued support behind Pennsaid ® and Oxytrol ® are ... marketwire.com Paladin Reports 2005 First Quarter Financial Results. - May 5, 2005 Paladin expects to launch Trelstar(R) in the fourth quarter of 2005. ... Trelstar(R) compliments our established urology franchise with Oxytrol(R) and ... $4.95 - Business Wire - ECNext Watson Receives US FDA Approval for RAPAFLO(TM) (Silodosin) for the … - Oct 9, 2008 ..."With our oxybutynin gel NDA under consideration with the FDA and plans to file our Trelstar(R) 6 month application later this year, Watson is in a unique ... RedOrbit Paladin Reports 2005 Second Quarter Results-Paladin Increases 2005 … - Jul 28, 2005 Paladin expects to launch Trelstar ® in the first quarter of 2006. ... Trelstar ® compliments our established urology franchise with Oxytrol ® and Vantas TM ... ccnmatthews.com Watson Pharmaceuticals, Inc. at CIBC World Markets 17th Annual … - Nov 8, 2006 And in the urology field, we have Trelstar, Oxytrol. We obviously have some pipelines. In addition to that we have contract licensing royalty business ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Event Brief of Q4 2004 Watson Pharmaceuticals, Inc. Earnings … - Feb 10, 2005 On TRELSTAR, can you just provide us the kind of the marketing hook that you're ... On the TRELSTAR, let me just start and Charlie can deal with the other ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Watson Pharmaceuticals, Inc. at CIBC World Markets Annual … - Apr 4, 2006 The brand side, urology, we had TRELSTAR, which was the product, ... The TRELSTAR was acquired in 2004 and launched in 2005 and see the growth support from ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com triptorelin Debiopharm registered, Mexico Debiopharm licensing … - Jan 10, 2005 The agent is marketed in the USA for the treatment of prostate cancer under the trade name TRELSTAR. triptorelin, triptorelin pamoate, BN 52014, BIM 21003, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Paladin annonce ses résultats du quatrième trimestre et de l'exercice... - Feb 22, 2006 Trelstar(MD) est un agoniste injectable de l'hormone de libération de la lutéinostimuline (LHRH ou GnRH) indiqué pour le traitement palliatif du cancer ... ccnmatthews.com Watson Pharmaceuticals Reports Second Quarter 2008 Results - Aug 6, 2008 Brand product sales for the second quarter of 2008 increased five percent or $4.5 million to $101.5 million , primarily due to higher sales of Trelstar(R). ... Genetic Engineering News - Genetic Engineering News (press release) Paladin Reports 2007 First Quarter Financial Results & Increases … - May 10, 2007 This increase was primarily attributed to increased promotion activities relating to Paladin's launch of Pennsaid(R), Metadol(R), Trelstar and PravASA(R), ... Genetic Engineering News - Genetic Engineering News (press release) Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing By … - May 28, 2008 In the US, the Watson portfolio includes: Oxytrol(R); TRELSTAR(R) LA; TRELSTAR(R) Depot; Androderm(R); AndroGel(R), under a co-promotion agreement with ... RedOrbit <P>This article has been removed and is no longer available.</P> | … - Aug 3, 2006 Canadian Corporate News; May 2, 2005 ; 700+ words ... ... subsidiary of Watson Pharmaceuticals, Inc. (NYSE:WPI) to market Trelstar(R) 3.75 mg and ... Pay-Per-View - Canadian Corporate News - HighBeam Research Urologists Should Recognize the Cardiac Safety of Prescribed … - Aug 5, 2008 In the US, the Watson urology portfolio includes: Oxytrol(R); TRELSTAR(R) LA; TRELSTAR(R) Depot; Androderm(R); ProQuin(R) XR, under a co-promotion agreement ... RedOrbit The Business Press, San Bernardino, Calif., business briefs column. - Apr 11, 2005 Trelstar is a synthetic hormone that suppresses the production of testosterone. To see more of The Business Press, or to subscribe to the newspaper, ... Free with registration - Business Press - AccessMyLibrary.com Event Brief of Q3 2005 Watson Pharmaceuticals, Inc. Earnings … - Nov 2, 2005 ...s team has done a great job on the launch of Trelstar with unit sales exceeding ... Trelstar also has increased the Co.'s strategic position within urology. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Watson's 3rd-qtr 2007 revenue hits $594.7M. - Nov 19, 2007 Watson's brand product sales jumped 9% to $93.5 million, due to increased income from the anti-testosterone treatments Trelstar depot and Trelstar LA ... $9.94 - Pharma Marketletter - Alacra Store Q3 2005 Watson Pharmaceuticals, Inc. Earnings Conference Call - Part... - Nov 2, 2005 One, just -- if you could just give us TRELSTAR, our revs in the quarter and year-to-date? And two, just Allen, a bigger picture question, I think one other ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Press Release: Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High... - Jun 3, 2008 DEPOT and TRELSTAR(R) LA (triptorelin pamoate for injectable suspension) for the palliative treatment of advanced prostate cancer ... DEPOT and TRELSTAR(R) ... Pay-Per-View - PR Newswire - HighBeam Research Are changes in US practices for androgen deprivation therapy financial... - Jun 16, 2008 Of note, Trelstar ® was the only LHRH analog that had increased usage in the post-MMA period, and was the only LHRH therapy that maintained its pre-MMA ... Nature.com Palliative treatment for advanced PCa now available: Watson … - May 1, 2005 Two formulations of triptorelin pamoate for injectable suspension (Trelstar Depot and Trelstar LA) from Watson Pharmaceuticals, Inc., are now available ... $4.95 - Urology Times - ECNext Paladin Reports Record Revenues for Third Quarter & Increases … - Nov 2, 2006 Increased selling and marketing expenses in 2006 have resulted primarily from increased promotion activities behind the launch of Twinject(R), Trelstar(R) ... Genetic Engineering News - Genetic Engineering News (press release) Paladin annonce ses résultats du premier trimestre de 2007 & réhausse... - May 10, 2007 Metadol(MD), Trelstar(MD) et PravASA(MD), ainsi qu'aux activités soutenues de promotion de Twinject(MD), Plan B(MD) et Oxytrol(MD). ... ccnmatthews.com Paladin annonce ses résultats du deuxième trimestre de 2005-Paladin … - Jul 28, 2005 Paladin prévoit lancer Trelstar(MD) dans le courant du premier trimestre de ... Trelstar(MD) renforce le positionnement de Paladin dans le domaine de ... ccnmatthews.com Paladin annonce des résultats record pour le quatrième trimestre et... - Feb 15, 2007 Les ventes des principales marques commercialisées en 2006, y compris Twinject(MD), Oxytrol(MD), Estring(MD), Plan B(MD), Trelstar(MD) et Pennsaid(MD) ont ... ccnmatthews.com Event Brief of Q1 2006 Watson Pharmaceuticals, Inc. Earnings … - May 9, 2006 The first one is on Trelstar. I wonder if you could break out sales of that; ... Trelstar sales were approximately $7 million for the period, which was flat ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2004 … - Feb 10, 2005 The Company expects to launch its TRELSTAR(R) DEPOT and TRELSTAR(R) LA (triptorelin pamoate) products for the palliative treatment of advanced prostate ... $4.95 - PR Newswire - ECNext Paladin Reports Record 2007 Fourth Quarter and Year End Results - Feb 28, 2008 The promotional efforts behind Trelstar ® , Twinject ® , Plan B ® , Pennsaid ® and Testim ® contributed to our strong organic growth. ... marketwire.com Paladin Reports 2008 Second Quarter Financial Results - Aug 7, 2008 The promotional activities driving selling and marketing expenses primarily relate to Paladin's launch of Seasonale TM , Tridural TM , Testim ® and Trelstar ... marketwire.com Press Release: Sales of Abarelix for the Treatment of Prostate Cancer... - Jan 15, 2007 Article: Debiopharm Announces U.S. NDA Filing of Trelstar 6-Month ... ... Once approved, Trelstar(R) will ... Development, Drugs, FDA, Hormones, ... Pay-Per-View - M2 Presswire - HighBeam Research Paladin Reports 2008 First Quarter Financial Results - May 15, 2008 This increase was primarily attributed to increased promotion activities relating to Paladin's launch of Seasonale TM , Tridural TM , Testim ® and Trelstar ... marketwire.com The Business Press, San Bernardino, Calif., business briefs column. - May 9, 2005 ..."Trelstar represents our third product deal with Watson and follows on our successful in-license and launch of Oxytrol late last year," Jonathan Ross ... Free with registration - Business Press - AccessMyLibrary.com Paladin Reports Record Third Quarter 2008 Financial Results - Nov 6, 2008 The promotional activities driving selling and marketing expenses primarily relate to Paladin's launch of Seasonale", Tridural", Testim® and Trelstar® as ... International Business Times <P>This article has been removed and is no longer available.</P> | … - Jun 23, 2008 Trelstar(R) LA 11.25 mg, 3 month slow release, is an injectable, luteinizing hormone-releasing hormone ... Canadian Corporate News ... Pay-Per-View - Canadian Corporate News - HighBeam Research Watson 1st-quarter profit rises 60 percent - May 1, 2008 ...segment increased nearly 14 percent to $115 million, helped by demand for its Ferrlecit iron-deficiency treatment and Trelstar prostate-cancer drug. ... Reuters Paladin annonce des résultats record pour le troisième trimestre et … - Nov 2, 2006 ...est principalement attribuable à un accroissement des activités de promotion liées au lancement de Twinject(MD), de Trelstar(MD) et de Trelstar LA(MD), ... ccnmatthews.com EDITED BRIEF - May 1, 2008 Will be introducing a new delivery system for Trelstar called MixJect which ... Strong product sales reflect solid YoverY growth of Trelstar and Ferrlecit. ... $54.00 - Thomson StreetEvents - Alacra Store Prostate technique questioned; Medical castration for localized... - Jul 9, 2008 Treatment with such drugs as leuprolide (Lupron, Viadur, Eligard), goserelin (Zoladex) and triptorelin (Trelstar) peaked at more than $1.23 billion in the ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Paladin annonce des résultats financiers records pour le troisième … - Nov 6, 2008 Seasonale MC , Plan BMD, Pennsaid(MD), Metadol(MD), Trelstar(MD) et Testim(MD), ... Tridural MC , Testim(MD) et Trelstar(MD), ainsi qu'aux activités ... marketwire.com Paladin annonce ses résultats financiers du deuxième trimestre de l' … - Aug 7, 2008 Cette augmentation est attribuable principalement aux activités de promotion liées au lancement de Seasonale MC , Tridural MC , Testim(MD) and Trelstar(MD) ... marketwire.com Paladin annonce ses résultats du premier trimestre de 2008 et... - May 15, 2008 Twinject(MD), Seasonale MC , Plan B(MD), Pennsaid(MD), Metadol(MD), Trelstar(MD), ... Tridural MC , Testim(MD) et Trelstar(MD), ainsi qu'aux activités ... marketwire.com Mylan beats estimates; Watson profit in line - Aug 6, 2008 Revenue from its higher margin brand-name products rose 5 percent to $101.5 million, helped by its Trelstar prostate cancer treatment. ... Reuters Paladin Reports Record 2006 Fourth Quarter and Year End Results - Feb 15, 2007 Revenues from the Company's key promoted brands including: Twinject(R), Oxytrol(R), Estring(R), Plan B(R), Trelstar(R), and Pennsaid(R) increased by 58% in ... Genetic Engineering News - Genetic Engineering News (press release) Diagnosis and management of endometriosis.(Disease/Disorder … - Aug 15, 2006 ...implanted triptorelin subcutaneously [Trelstar Depot]) for six months Nafarelin (Synarel) Pain relief 200 mcg Expensive; intranasally significant twice ... $4.95 - American Family Physician - ECNext Article: STROKE Controlling homocyste ... - The Washington Post | … - Mar 8, 2005 ...offer their ... injectable suspension), a palliative treatment for advanced prostate cancer. MIXJECT(R) combines the proven efficacy of TRELSTAR ... ... Pay-Per-View - Washington Post - HighBeam Research Watson Pharmaceuticals, Inc. at Credit Suisse Healthcare Conference -... - Nov 15, 2007 We also finished our OXY gel study, which we will talk about in detail, and Trelstar basically the line extension was also completed. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Watson Pharmaceuticals, Inc. at Bank of America Health Care … - May 30, 2007 ...are also marketing the (inaudible) exclusive urologist space, and Oxytrol is a product being approved to marketplace almost four years now, Trelstar h. Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Watson Pharmaceuticals, Inc. at CIBC World Markets Annual … - Apr 11, 2007 In 2004, we acquired Silodosin, which is a BPH product, and Trelstar, which is a prostate cancer product. During that year, we had refocused business into ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Top 50 packagers: pharmaceutical.(TOP 200 PACKAGERS)(Company … - Jul 1, 2007 Zevalin 26 Watson Pharmaceuticals Oxytrol; Trelstar; 1 Inc. Androderm Corona, Calif. 27 Novo Nordisk A/S Vagifem; Activelle; 1 Bagsvaerd, ... Free with registration - Food & Drug Packaging - AccessMyLibrary.com The Less-Flashy Prostate Cancer Treatment - Feb 26, 2008 After androgen-deprivation therapy with drugs such as AstraZeneca's (NYSE: AZN) Zoladex or Watson Pharmaceuticals' (NYSE: WPI) Trelstar, prostate cancer ... fool.com Paladin and Auxilium Sign Exclusive Distribution Agreement for Testim'... - Dec 12, 2006 ...strengthen our growing urology franchise which includes Oxytrol ® and Trelstar ® ", said Jonathan Ross Goodman, President and CEO of Paladin Labs ... ccnmatthews.com Q1 2006 Watson Pharmaceuticals, Inc. Earnings Conference Call - Final. - May 9, 2006 ...the following products -- silodosin for BPH; oxybutynin gel, new formulation for overactive bladder; and the long-acting formulation of Trelstar. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Q2 2005 Watson Pharmaceuticals, Inc. Earnings Conference Call - Final. - Jul 27, 2005 We launched Trelstar in early April and the launch is doing very well. It's a nice product that fits within our specialty focus providing more depth to the ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Paladin Reports Record Revenue for Third Quarter: Sales of Key … - Oct 27, 2005 In 2006, Paladin will be launching more products, including Trelstar ® and Vantas TM , two products for the treatment of prostate cancer. ... ccnmatthews.com Prostate cancer: New studies of combination therapy. - Jan 1, 2005 The major LHRH agonists are goserelin (Zoladex), leuprolide (Lupron, Eligard, Viadur), and triptorelin (Trelstar). They are equally effective and equally ... Free with registration - Harvard Men's Health Watch - AccessMyLibrary.com Debiopharm SA Announces Marketing Approval for a New Formulation of … - Feb 7, 2005 Decapeptyl(R), the leading product of Ipsen, and Trelstar(R) (1- and 3-month). Together, their combined sales were in excess of $1.8 bn in 2004. ... Free with registration - PR Newswire - AccessMyLibrary.com Dyax Corp. And Debiopharm SA Restructure Development Agreement for … - Dec 20, 2005 ...leading marketed products; Decapeptyl(R), the leading product of Ipsen; and Trelstar(R) (1-and 3-month), marketed by Watson Pharmaceuticals, Inc. ... RedOrbit GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE … - Feb 1, 2005 Decapeptyl(r), the leading product of Ipsen, and Trelstar(r) (1-and 3-month). Together, their combined sales are in excess of $ 1.8 bn in 2004. ... Entrepreneur Debiopharm and Neovacs Sign License and Equity Agreement for the … - Jun 27, 2005 Decapeptyl(R), the leading product of Ipsen, and Trelstar(R) (1-and 3-month) a registered trademark of Watson Pharmaceuticals, Inc. Together, ... RedOrbit Event Brief of Q1 2006 Watson Pharmaceuticals, Inc. Earnings … - May 9, 2006 The long-acting formulation of Trelstar. 4. Silodosin: 1. Enrollment in the Phase III trial is complete with 900 total patients enrolled in the two studies. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com The 'CAP' is out of the bag; should you participate? CMS's Competitive... - Aug 1, 2005 All other LHRH agonists, such as triptorelin pamoate (Trelstar), goserelin acetate (Zoladex), and leuprolide implant (Viadur) are included. ... Free with registration - Urology Times - AccessMyLibrary.com Debiopharm SA Presented Results of a Double-Blind Placebo-Controlled ... - Feb 9, 2006 ...leading marketed products; Decapeptyl(R), the leading product of Ipsen; and Trelstar(R) (1-and 3-month), marketed by Watson Pharmaceuticals, Inc. ... Free with registration - PR Newswire - AccessMyLibrary.com Watson Pharmaceuticals, Inc. at Banc of America Securities 2006... - May 18, 2006 ...(indiscernible) urology be the focus on OXYTROL (indiscernible) market TRELSTAR prostate cancer, and the Androderm, and also have the nephrology area as ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com FAQs, Part 2: new rules impact injection payments: here are answers... - Apr 1, 2005 Therefore, this is the correct code to use for goserelin acetate (Zoladex), triptorelin pamoate (Trelstar), and leuprolide acetate (Lupron, Eligard) for ... Free with registration - Urology Times - AccessMyLibrary.com Hormone therapy for prostate cancer (androgen deprivation therapy, or... - Jun 27, 2008 They include goserelin (Zoladex), leuprolide (Lupron), and triptorelin (Trelstar Depot). Antiandrogens. These drugs often are used along with LH-RH agonists ... MSN Health & Fitness Watson's OAI lifted and Goa manufacturing transfer on track - May 5, 2008 Product sales increased 9 per cent due to an improved contribution from Ferrlecit (sodium ferric gluconate) and Trelstar (triptorelin palmoate). ... In-PharmaTechnologist.com The Less-Flashy Prostate Cancer Treatment - Feb 27, 2008 After androgen-deprivation therapy with drugs such as AstraZeneca 's (NYSE: AZN) Zoladex or Watson Pharmaceuticals ' (NYSE: WPI) Trelstar, prostate cancer ... Money Times - The Money Times Debiopharm honors cancer research in Lausanne - Nov 10, 2006 The company is known in particular for having several products such as Eloxatin®, treatment of choice for colorectal cancer, and Decapeptyl® and Trelstar® ... innovations report Look for these coding, reimbursement changes in 2006: new CPT codes … - Dec 1, 2005 For example, 96402 (antineoplastic hormonal injection therapy) is the code for all LHRH agonist drugs--such as triptorelin pamoate (Trelstar), ... Free with registration - Urology Times - AccessMyLibrary.com Learn about Flutamide from Consumer Reports Health. - Jan 12, 2008 ...or triptorelin [Trelstar]) to treat certain types of prostate cancer. Flutamide is in a class of medications called nonsteroidal antiandrogens. ... consumerreports.org Paladin Reports 2006 First Quarter Financial Results - May 11, 2006 ..."We exceeded our sales goals for the quarter, and are preparing to launch Vantas ® , and Trelstar ® , two products for the treatment of prostate cancer that ... ccnmatthews.com Watson Pharmaceuticals, Inc. - Sep 17, 2007 Key products include Ferrlecit, an intravenous iron for use in the dialysis setting; Trelstar, an LHRH agonist for treating advanced prostate cancer; ... $9.94 - Chain Drug Review - Alacra Store Personnel; Biopharmaceutical company names senior vice president, … - Jan 17, 2005 ...in first-line colorectal cancer, commercialization of Ellence and Aromasin for breast cancer, and the launch of Trelstar for prostate and breast cancer. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Debiopharm, SA; Company inks licensing agreement in Mexico for … - Jan 26, 2005 In the United States, Decapeptyl is marketed as Trelstar. "Rowfarma and Debiopharm recognized the good fit between the market potential in Mexico for ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Product Licensing; Company inks licensing agreement in Mexico for … - Jan 28, 2005 In the United States, Decapeptyl is marketed as Trelstar. "Rowfarma and Debiopharm recognized the good fit between the market potential in Mexico for ... Pay-Per-View - Drug Week - Factiva, from Dow Jones |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |